| MS patients | Controls |
---|
 | Total | R-R | S-P |  |
---|
 | N = 114 (%) | N = 79 (%) | N = 35 (%) | N = 121 (%) |
---|
Genotype frequency | Â | Â | Â | Â |
G/G | 23 (20.2%) | 16 (20.3%) | 7 (20.0%) | 25 (20.7%) |
G/A | 65 (57.0%) | 44 (55.7%) | 21 (60.0%) | 63 (52.1%) |
A/A | 26 (22.8%) | 19 (24.1%) | 7 (20.0%) | 33 (27.3%) |
Allele frequency | Â | Â | Â | Â |
G | 111 (48.7%) | 76 (48.1%) | 35 (50.0%) | 113 (46.7%) |
A | 117 (51.3%) | 82 (51.9%) | 35 (50.0%) | 129 (53.3%) |
- There was no significant difference in the distributions of -670 polymorphisms in Apo-1/Fas gene between MS patients and control subjects. Furthermore, there were no significant differences in the distributions of -670 polymorphisms in the Apo-1/Fas gene between patients with a relapsing-remitting course and those with a secondary-progressive course or between patients with either course and controls (P > 0.05).